Furthermore, the KEYNOTE-048 study using anti-PD-1 therapy in patients with R/M HNSCC who had not received prior treatment with platinum-based chemotherapy also revealed a clinical benefit suggesting the use of pembrolizumab as an appropriate fist-line treatment for PD-L1+ HNSCC [117]. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.